Kintor Pharmaceutical Ltd (HK:9939) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kintor Pharmaceutical Limited has successfully enrolled the first participant in its pivotal clinical trial for KX-826 tincture, aimed at treating male androgenetic alopecia in China. This step marks significant progress in a study designed to assess the efficacy and safety of their innovative treatment. Additionally, their long-term safety trial has shown promising results, indicating excellent safety and tolerability of the drug.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.